Palisade Bio Inc Financials
This page shows Palisade Bio Inc (PALI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 was a balance-sheet reset, with new financing overwhelming annual cash burn and rebuilding the company’s operating runway.
FY2025 changed the funding model: a$134.4M financing inflow turned a business that had been operating with roughly$11M -$12M of annual cash burn into one holding$133.4M of cash against only$5.0M of liabilities. That shifts the near-term story from survival financing to how quickly management deploys cash into research and overhead.
Across FY2022-FY2024, operating cash burn stayed close to net loss, which means the losses were mostly real cash spending rather than accounting-only charges. In FY2025 that relationship loosened, with net loss at
The expense mix shifted even though total spending stayed heavy: R&D fell from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Palisade Bio Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Palisade Bio Inc carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 28.95, Palisade Bio Inc holds $28.95 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Palisade Bio Inc generates a -13.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -192.7% the prior year.
Palisade Bio Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Palisade Bio Inc generates $0.65 in operating cash flow (-$10.8M OCF vs -$16.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Palisade Bio Inc earns $-1805.6 in operating income for every $1 of interest expense (-$18.1M vs $10K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Palisade Bio Inc generated $0 in revenue in fiscal year 2025.
Palisade Bio Inc's EBITDA was -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.5% from the prior year.
Palisade Bio Inc reported -$16.8M in net income in fiscal year 2025. This represents a decrease of 16.2% from the prior year.
Palisade Bio Inc earned $-0.30 per diluted share (EPS) in fiscal year 2025. This represents an increase of 97.1% from the prior year.
Cash & Balance Sheet
Palisade Bio Inc held $133.4M in cash against $0 in long-term debt as of fiscal year 2025.
Palisade Bio Inc had 159M shares outstanding in fiscal year 2025. This represents an increase of 5658.9% from the prior year.
Margins & Returns
Palisade Bio Inc's ROE was -13.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 179.7 percentage points from the prior year.
Capital Allocation
Palisade Bio Inc invested $10.2M in research and development in fiscal year 2025. This represents a decrease of 36.3% from the prior year.
PALI Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $6.0M | N/A | $1.4M-16.8% | $1.7M+76.3% | $950K | N/A | $16.0M+508.8% | $2.6M |
| SG&A Expenses | $4.4M | N/A | $1.5M+30.8% | $1.2M-14.1% | $1.4M | N/A | $1.5M-8.0% | $1.6M |
| Operating Income | -$10.7M | N/A | -$2.9M-2.8% | -$2.8M-23.1% | -$2.3M | N/A | -$3.6M+14.7% | -$4.2M |
| Interest Expense | $1K | N/A | $5K+150.0% | $2K+100.0% | $1K | N/A | $6K+200.0% | $2K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$9.6M | N/A | -$2.9M-3.0% | -$2.8M-24.8% | -$2.2M | N/A | -$3.5M+14.5% | -$4.1M |
| EPS (Diluted) | $-0.05 | N/A | $-0.38 | $-0.58-23.4% | $-0.47 | N/A | $-2.32+30.1% | $-3.32 |
PALI Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $133.3M-0.8% | $134.3M+1826.6% | $7.0M+4.6% | $6.7M-18.6% | $8.2M-24.7% | $10.9M+16.5% | $9.3M-27.5% | $12.9M |
| Current Assets | $133.2M-0.7% | $134.2M+1865.7% | $6.8M+5.9% | $6.4M-18.3% | $7.9M-24.8% | $10.5M+18.3% | $8.9M-28.0% | $12.3M |
| Cash & Equivalents | $132.6M-0.6% | $133.4M+2451.8% | $5.2M-3.5% | $5.4M-25.1% | $7.2M-26.4% | $9.8M+22.2% | $8.0M-29.2% | $11.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.0M+19.9% | $5.0M+32.0% | $3.8M-7.1% | $4.0M+41.6% | $2.9M-15.6% | $3.4M+24.2% | $2.7M-6.6% | $2.9M |
| Current Liabilities | $5.6M+21.2% | $4.6M+33.3% | $3.5M-12.4% | $4.0M+43.0% | $2.8M-14.2% | $3.2M+20.7% | $2.7M-5.5% | $2.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $127.4M-1.6% | $129.4M+3928.0% | $3.2M+22.6% | $2.6M-50.9% | $5.3M-28.8% | $7.5M+13.4% | $6.6M-33.6% | $9.9M |
| Retained Earnings | N/A | N/A | N/A | $141.0M+2.0% | $138.2M+1.7% | $135.9M+2.5% | $132.6M+202.7% | -$129.1M |
PALI Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.9M-23.7% | -$3.1M+11.5% | -$3.6M-95.5% | -$1.8M+22.1% | -$2.3M+2.0% | -$2.4M+24.0% | -$3.1M+10.5% | -$3.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0 | $0 | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$2.4M+24.0% | -$3.1M | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | $0 | $0 | N/A |
| Financing Cash Flow | $3.1M-97.6% | $131.3M+3805.2% | $3.4M+83975.0% | $4K+101.6% | -$258K-106.2% | $4.2M+2412.2% | -$180K-105.0% | $3.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PALI Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -7.5% | N/A | -89.3%+17.0pp | -106.3%-64.4pp | -41.8% | N/A | -52.8%-11.8pp | -41.0% |
| Return on Assets | -7.2% | N/A | -41.1%+0.6pp | -41.8%-14.5pp | -27.2% | N/A | -37.4%-5.6pp | -31.7% |
| Current Ratio | 23.71-5.2 | 28.95+27.0 | 1.96+0.3 | 1.62-1.2 | 2.84-0.4 | 3.24-0.1 | 3.31-1.0 | 4.34 |
| Debt-to-Equity | 0.050.0 | 0.04-1.1 | 1.17-0.4 | 1.54+1.0 | 0.54+0.1 | 0.45+0.0 | 0.41+0.1 | 0.29 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Palisade Bio Inc's annual revenue?
Palisade Bio Inc (PALI) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Palisade Bio Inc profitable?
No, Palisade Bio Inc (PALI) reported a net income of -$16.8M in fiscal year 2025.
What is Palisade Bio Inc's EBITDA?
Palisade Bio Inc (PALI) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Palisade Bio Inc's return on equity (ROE)?
Palisade Bio Inc (PALI) has a return on equity of -13.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Palisade Bio Inc's operating cash flow?
Palisade Bio Inc (PALI) generated -$10.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Palisade Bio Inc's total assets?
Palisade Bio Inc (PALI) had $134.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Palisade Bio Inc spend on research and development?
Palisade Bio Inc (PALI) invested $10.2M in research and development during fiscal year 2025.
What is Palisade Bio Inc's current ratio?
Palisade Bio Inc (PALI) had a current ratio of 28.95 as of fiscal year 2025, which is generally considered healthy.
What is Palisade Bio Inc's debt-to-equity ratio?
Palisade Bio Inc (PALI) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Palisade Bio Inc's return on assets (ROA)?
Palisade Bio Inc (PALI) had a return on assets of -12.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Palisade Bio Inc's cash runway?
Based on fiscal year 2025 data, Palisade Bio Inc (PALI) had $133.4M in cash against an annual operating cash burn of $10.8M. This gives an estimated cash runway of approximately 148 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Palisade Bio Inc's Piotroski F-Score?
Palisade Bio Inc (PALI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Palisade Bio Inc's earnings high quality?
Palisade Bio Inc (PALI) has an earnings quality ratio of 0.65x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Palisade Bio Inc cover its interest payments?
Palisade Bio Inc (PALI) has an interest coverage ratio of -1805.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Palisade Bio Inc?
Palisade Bio Inc (PALI) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.